CD79A and myeloid sarcoma: Convalescent humoral recall responses were analyzed by comparing RBD-specific IgG, IgM, and IgA antibodies between SARS-CoV-2 experienced HCs, RA-MTX, and MS-OCR patients before vaccination (T0) (Figure 2a–c and Figure 2—figure supplement 1a, b).